许毓楷,张智伟

• 1:广东省心血管病研究所广东省人民医院心儿科

摘要(Abstract)：

房间隔缺损（ASD）患者常合并三尖瓣反流（TR）。严重TR会增加心血管疾病发病率和死亡率。随着心导管技术的发展，ASD介入封堵术已成为代替外科手术的一种有效治疗方法，三尖瓣的介入治疗也有了新的尝试。但目前对于ASD合并TR患者的研究较少，对于ASD合并TR的患者在ASD闭合后三尖瓣的变化情况以及严重TR的治疗策略仍存在争议。本文就ASD合并TR的机制、诊断以及治疗进行阐述。

关键词(KeyWords)： 房间隔缺损;三尖瓣反流;ASD介入封堵术;三尖瓣成形术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 许毓楷,张智伟

参考文献(References)：

• [1] Rao P.S. Management of congenital heart disease:state of the art;part I-acyanotic heart defects[J]. Children(Basel),2019,6(3):42.
• [2] Arsalan M, Walther T, Smith RL 2nd, et al. Tricuspid regurgitation diagnosis and treatment[J]. Eur Heart J,2017,38(9):634-638.
• [3] Dreyfus GD, Corbi PJ, Chan KM, et al. Secondary tricuspid regurgitation or dilatation:which should be the criteria for surgical repair[J]? Ann Thorac Surg,2005,79(1):127-132.
• [4] Prihadi EA, van der Bijl P, Gursoy E, et al. Development of signifi cant tricuspid regurgitation over time and prognostic implications:new insights into natural history[J]. Eur Heart J,2018,39(39):3574-3581.
• [5] Nakagawa K, Akagi T,Taniguchi M,et al. Transcatheter closure of atrial septal defect in a geriatric population[J]. Catheter Cardiovasc Interv, 2012,80(1):84-90.
• [6] Cherry SV, Jain P, Rodriguez-Blanco YF, et al. Noninvasive evaluation of native valvular regurgitation:a review of the2017 American Society of Echocardiography guidelines for the perioperative echocardiographer[J]. J Cardiothorac Vasc Anesth,2018,32(2):811-822.
• [7] Rodés-Cabau J, Taramasso M, O’Gara PT. Diagnosis and treatment of tricuspid valve disease:current and future perspectives[J].Lancet,2016,388(10058):2431-2442.
• [8]蒋连勇，丁芳宝，黄健兵，等.房间隔缺损合并三尖瓣反流行房间隔缺损封堵术的疗效分析[J].中国胸心血管外科临床杂志，2014,21(5):624-627.
• [9] Takaya Y, Akagi T, Kijima Y, et al. Functional tricuspid regurgitation after transcatheter closure of atrial septal defect in adult patients:long-term follow-up[J]. JACC Cardiovasc Interv, 2017,10(21):2211-2218.
• [10] Chen L,Shen J,Shan X, et al. Improvement of tricuspid regurgitation after transcatheter ASD closure in older patients[J].Herz, 2018, 43(6):529-534.
• [11] Bach Y,Abrahamyan L,Lee DS,et al. Long-term outcomes of adults with tricuspid regurgitation following transcatheter atrial septal defect closure[J]. Can J Cardiol,2022,38(3):330-337.
• [12] Fang F, Wang J, Yip GW, et al. Predictors of mid-term functional tricuspid regurgitation after device closure of atrial septal defect in adults:impact of pre-operative tricuspid valve remodeling[J]. Int J Cardiol,2015,187:447-452.
• [13] Toyono M, Krasuski RA, Pettersson GB, et al. Persistent tricuspid regurgitation and its predictor in adults after percutaneous and isolated surgical closure of secundum atrial septal defect[J]. Am J Cardiol,2009,104(6):856-861.
• [14] Le Gloan L, Legendre A, Iserin L, et al. Pathophysiology and natural history of atrial septal defect[J]. J Thorac Dis,2018,10(Suppl 24):S2854-S2863.
• [15] Calafi ore AM, Bartoloni G, Al Amri H, et al. Functional tricuspid regurgitation and the right ventricle:what we do not know is more than we know[J]. Expert Rev Cardiovasc Ther,2014,10(11):1351-1366.
• [16] Ali M, Salah El-Din H, Bakhoum S, et al. Feasibility of percutaneous closure of atrial septal defects in adults under transthoracic echocardiography guidance using the fi gulla atrial septal defect occluder device[J]. J Saudi Heart Assoc,2018,30(1):21-27.
• [17] De Meester P, Van De Bruaene A, Herijgers P, et al. Increased pulmonary artery pressures during exercise are related to persistent tricuspid regurgitation after atrial septal defect closure[J]. Acta Cardiol,2013,68(4):365-372.
• [18] Mutlak D, Aronson D, Lessick J, et al. Functional tricuspid regurgitation in patients with pulmonary hypertension:is pulmonary artery pressure the only determinant of regurgitation severity[J]?Chest,2009,135:115-121.
• [19] Silvestry FE, Cohen MS, Armsby LB, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale:from the American society of echocardiography and society for cardiac angiography and interventions[J]. J Am Soc Echocardiogr,2015,28(8):910-958.
• [20] Boudoulas KD, Marmagkiolis K, Boudoulas H. Atrial septal defect sizing and transcatheter closure[J]. Cardiology,2019,142(2):105-108.
• [21] Deri A, English K. Echocardiographic assessment of left to right shunts:atrial septal defect, ventricular septal defect,atrioventricular septal defect, patent arterial duct[J]. Echo Res Pract,2018,5(1):R1-R16.
• [22]黄国明，丁仲如，涂晓文，等.巨大房间隔缺损介入封堵治疗的可行性和安全性评价[J].国际心血管病杂志，2008,35(3):188-191.
• [23]孙锟，李奋，张智伟，等.儿童常见先天性心脏病介入治疗专家共识[J].中华儿科杂志，2015,53(1):17-24.
• [24] Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography[J]. J Am Soc Echocardiogr,2003,16(7):777-802.
• [25] Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading scheme[J]. Eur Heart J Cardiovasc Imaging,2017,18(12):1342-1343.
• [26] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. Circulation,2014,129(23):2440-2492.
• [27] Dreyfus GD, Martin RP, Chan KM, et al. Functional tricuspid regurgitation:a need to revise our understanding[J]. J Am Coll Cardiol,2015,65(21):2331-2336.
• [28] Toyono M, Fukuda S, Gillinov AM, et al. Diff erent determinants of residual tricuspid regurgitation after tricuspid annuloplasty:comparison of atrial septal defect and mitral valve prolapse[J]. J Am Soc Echocardiogr,2009,22(8):899-903.
• [29]王宝珠，孟凡华，马翔，等.经导管与外科手术治疗继发孔型房间隔缺损的Meta分析[J].中国介入心脏病学杂志，2018,26(8):447-456.
• [30]王忠超，王琦光，张端珍，等.先天性心脏病介入治疗术中及围术期严重并发症分析[J].中国介入心脏病学杂志，2019,27(7):386-390.
• [31] Rodés-Cabau J, Hahn RT, Latib A, et al. Transcatheter therapies for treating tricuspid regurgitation[J]. J Am Coll Cardiol,2016,67(15):1829-1845.
• [32] O’Neill BP, Negrotto S, Yu D, et al. Caval valve implantation for tricuspid regurgitation:insights from the United States caval valve registry[J]. J Invasive Cardiol,2020,32(12):470-475.
• [33] Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation:6-month outcomes of the triluminate single-arm study[J]. Lancet,2019,394(10213):2002-2011.
• [34] Campelo-Parada F, Perlman G, Philippon F, et al. First-inman experience of a novel transcatheter repair system for treating severe tricuspid regurgitation[J]. J Am Coll Cardiol,2015,66(22):2475-2483.
• [35] Chikwe J, Anyanwu AC. Surgical strategies for functional tricuspid regurgitation[J]. Semin Thorac Cardiovasc Surg,2010,22(1):90-96.
• [36] Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease(version 2012):the joint task force on the management of valvular heart disease of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur J Cardiothorac Surg,2012,42(4):S1-S44.
• [37] Nassif M, van der Kley F, Abdelghani M, et al. Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect[J]. Eur Heart J Cardiovasc Imaging,2019,20(2):225-232.
• [38] Yalonetsky S, Lorber A. Comparative changes of pulmonary artery pressure values and tricuspid valve regurgitation following transcatheter atrial septal defect closure in adults and the elderly[J].Congenit Heart Dis,2009,4(1):17-20.
• [39] Martin-Garcia AC, Dimopoulos K, Boutsikou M, et al. Tricuspid regurgitation severity after atrial septal defect closure or pulmonic valve replacement[J]. Heart,2020,106(6):455-461.
• [40] Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction[J]. Circulation,2019,140(3):196-206.
• [41] Kelly BJ, Ho Luxford JM, Butler CJ, et al. Severity of tricuspid regurgitation is associated with long-term mortality[J]. J Thorac Cardiovasc Surg,2018,155(3):1032-1038.
• [42] Chorin E, Rozenbaum E, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes[J]. Eur Heart J Cardiovasc Imaging,2020,21(2):157-165.
• [43] Oster M, Bhatt AB, Zaragoza-Macias E, et al. Interventional therapy versus medical therapy for secundum atrial septal defect:a systematic review(part 2)for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation,2019,139(14):e814-e830.